证券代码：002393 证券简称：力生制药 公告编号：2025-078 天津力生制药股份有限公司 第八届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 天津力生制药股份有限公司(以下简称"公司"或"本公司")于2025年11月28日以书面方式 发出召开第八届董事会第二次会议的通知，会议于2025年12月05日以通讯表决方式召开。 会议应参加的董事9名，实际参加的董事9名，符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 1、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于回购注销2022 年股权激励计划部分激励对象已获授但尚未解除限售的限制性股票的议案》。 该议案尚需提交股东会审议。 具体内容详见中国证券报、证券时报及巨潮资讯网（www.cninfo.com.cn）披露的《关 于回购注销2022年股权激励部分激励对象已获授但尚未解除限售的限制性股票的公告》 （公告编号：2025-082）。 2、会议以7票同意、0票反对、0票弃权的表决结果，审议通过了《关于2022年股权 激励计划首次授 ...

天津力生制药股份有限公司 第八届董事会薪酬与考核委员会第二次会议 对相关事项的核查意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股 权激励管理办法》（以下简称"《管理办法》"）《深圳证券交易所上市公司自律 监管指引第1号——主板上市公司规范运作》等相关法律、法规及《公司章程》 的有关规定，天津力生制药股份有限公司（以下简称"公司"）第八届董事会 薪酬与考核委员会于2025年12月5日召开第二次会议，本次会议应参加的委员 三名，实际参加的委员三名。全体委员本着客观公正的立场，就公司股权激励 相关事项发表审查意见如下： 一、关于回购注销2022年股权激励计划部分激励对象已获授但尚未解除限 售的限制性股票的事项 本次激励计划预留授予的激励对象具备《公司法》《证券法》等法律法规 和规范性文件以及《公司章程》规定的任职资格，符合《管理办法》规定的激 励对象条件，符合公司《2024年限制性股票激励计划（草案）》及其摘要规定 的激励对象范围，其作为公司本次股权激励计划激励对象的主体资格合法、有 效，激励对象获授限制性股票的条件已成就。公司本次授予激励对象人员标准 与公司2025年第一次临时股东大会批准 ...

关于 2022 年限制性股票激励计划预留授予部分 第一次解除限售并上市流通的提示性公告 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公告不 存在虚假记载、误导性陈述或者重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2025-076 天津力生制药股份有限公司 重要提示： 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于2025年11月13日召开第 八届董事会第一次会议审议通过了《关于2022年限制性股票激励计划预留授予部分第一个 解除限售期解除限售条件成就的议案》。公司董事会认为公司2022年限制性股票激励计划 预留授予部分的第一个解除限售期已符合解除限售条件。 根据公司2022年第五次临时股东大会审议授权及公司2022年限制性股票激励计划相关 规定，公司办理了2022年限制性股票激励计划预留授予部分第一次解除限售并上市流通手 续，现就有关事项说明如下： 一、公司股权激励计划简述及实施情况 1.2022年10月28日，公司召开第七届董事会第十五次会议，会议审议通过了《关于公 司2022年限制性股票激励计划（草案）及其摘要的议案》《关于公司2022年限制性股票激 ...

Core Viewpoint - The company aims to rejuvenate its brand image and connect with younger audiences through cultural storytelling and innovative marketing strategies, particularly by utilizing online short dramas to convey its values and heritage [1][2]. Group 1: Cultural and Brand Strategy - The company believes that culture and innovation are key to revitalizing traditional brands and engaging consumers [1]. - The initiative to produce online short dramas is part of a broader strategy to enhance brand recognition and emotional connection with the audience, particularly among younger demographics [1][2]. - The company has established a "1+3" corporate culture system, which supports the dissemination of its cultural values through creative formats like short dramas [2]. Group 2: Long-term Vision and Collaboration - The company prioritizes long-term cultural impact over short-term marketing gains, focusing on creating culturally significant works that resonate with its brand identity [3]. - The company is exploring collaborations with various institutions to innovate and expand its cultural outreach, aiming to create impactful cultural products that embody the spirit of traditional brands [3]. Group 3: Digital Transformation and Business Expansion - The company has a clear plan for integrating AI and digital technologies into its operations, enhancing traditional processes in production, management, and marketing [4]. - The company is looking to expand its business into new areas, including traditional Chinese medicine and the broader health sector, while maintaining a focus on quality and cultural values [4].

Core Viewpoint - The company aims to rejuvenate its brand image and connect with younger audiences through cultural storytelling and innovative marketing strategies, particularly by utilizing online short dramas to convey its values and heritage [1][2]. Group 1: Cultural and Brand Strategy - The company believes that culture and innovation are key to revitalizing its traditional brand image and engaging consumers [1]. - The initiative to produce online short dramas is part of a broader strategy to communicate the company's values of "doing good and making good medicine" and to resonate emotionally with audiences [1][2]. - The company has established a "1+3" corporate culture system, which has matured to the point where it can be effectively communicated through creative formats like short dramas [2]. Group 2: Long-term Vision and Collaboration - The company prioritizes long-term cultural impact over short-term marketing gains, focusing on a clear plan for cultural narrative and brand communication [3]. - The company is exploring collaborations with various institutions to create culturally significant works that embody the spirit of traditional brands [3]. - The company maintains an open attitude towards cross-industry collaborations and innovative formats, adjusting strategies based on effectiveness [3]. Group 3: Digital Transformation and Business Expansion - The company has a clear plan for integrating AI and digital technologies into its operations, aiming to enhance traditional processes and develop new digital business avenues [4]. - The company intends to expand its business into areas such as traditional Chinese medicine and the broader health sector, while also considering advanced fields like synthetic biology and gene therapy [4]. - The company emphasizes quality and cultural values in every product it develops, ensuring alignment with its mission and heritage [4].

格隆汇11月21日｜力生制药(002393.SZ)低开低走，一度跌4.23%至20.16元，股价创7月15日以来逾4个月新低。力生制药公告，公司副总经理郭晓燕拟自公告 披露15个交易日后3个月内以集中竞价方式减持不超11200股，占剔除回购后总股本0.0044%，股份来源为2022年限制性股票激励计划授予股份。(格隆汇) ...

Core Insights - On November 20, several companies disclosed their share repurchase and reduction plans, indicating varying levels of confidence in their stock performance [1] Group 1: Share Repurchase Plans - Eddie Precision plans to repurchase A-shares worth between 100 million to 200 million yuan [2] - Aviation Materials plans to repurchase shares worth between 50 million to 100 million yuan [2] - Changshu Bank's executives plan to increase their holdings by no less than 550,000 shares [2] Group 2: Share Reduction Plans - New Hongze's major shareholder reduced their holdings during a period of abnormal stock fluctuations [2] - General Electric's Singapore company plans to reduce its holdings by no more than 3% in China Xidian [2] - Senior management of Lifespring Pharmaceutical plans to reduce their holdings by no more than 0.0044% [2] - Shareholder Zhoushan Ruihao of Wan Feng plans to reduce holdings by no more than 1.75% [2] - Shareholders of Dongxin plan to collectively reduce holdings by no more than 0.71% [2] - Haigang Group, a shareholder of Hainan Mining, plans to reduce holdings by no more than 0.75% [2] - Actual controller Zhang Guifeng of Fulongma reduced 3.7812 million shares from November 19 to November 20 [2] - Shareholder Dongguan Kechuang Investment Group of Shengyi Electronics plans to reduce holdings by no more than 1% [2] - Shareholder Qinyi Partnership of Yayi Technology plans to reduce holdings by no more than 0.25% [2] - Controlling shareholder Yuansi Industrial of New City plans to reduce holdings by no more than 3% [2] - Controlling shareholder of Kaishan plans to reduce holdings by no more than 1% [2] - The largest shareholder of Tuo Jing Technology, the National Fund, plans to reduce holdings by no more than 3% [2] - Controlling shareholder Li Zheng of Wajinjiao plans to reduce holdings by no more than 3% [2] - Shareholder Shanxi Huaxin Hai of Baose plans to reduce holdings by no more than 1% [2] - Shareholders of Huaya Intelligent plan to collectively reduce holdings by 399.21 million shares, accounting for 2.98% of total share capital [2] - Directors and executives of Changxin Bochuang plan to collectively reduce holdings by no more than 0.05% [2] - Shareholders of Longxun plan to collectively reduce holdings by no more than 2.63% [2] - Some directors and executives of Fulede plan to collectively reduce holdings by no more than 0.0104% [2]

Core Points - The company, Lisheng Pharmaceutical, announced that senior management personnel, Guo Xiaoyan, plans to reduce her holdings in the company by selling up to 11,200 shares within three months after a 15 trading day period from the announcement date [2] Summary by Category Company Announcement - Guo Xiaoyan holds 114,800 shares, representing 0.0446% of the company's total share capital and 0.0448% of the total share capital excluding shares in the repurchase account [2] - The planned reduction in shareholding will not exceed 0.0044% of the total share capital after excluding shares in the repurchase account [2]

Core Viewpoint - The company, Lisheng Pharmaceutical, announced that senior management personnel Guo Xiaoyan plans to reduce holdings of the company's shares through centralized bidding, with a total reduction not exceeding 11,200 shares, which represents a maximum reduction of 0.0044% of the company's total share capital after excluding shares in the repurchase special account [1] Summary by Category - **Company Announcement** - Lisheng Pharmaceutical disclosed that Guo Xiaoyan intends to reduce her shareholding in the company [1] - The planned reduction is limited to a total of 11,200 shares [1] - The reduction accounts for a maximum of 0.0044% of the total share capital after excluding repurchased shares [1]

Core Viewpoint - The company, Lisheng Pharmaceutical (002393.SZ), announced that senior management personnel, Guo Xiaoyan, plans to reduce her shareholding in the company by selling up to 11,200 shares within three months after a 15 trading day period from the announcement date [1] Summary by Categories Shareholding Reduction Plan - Guo Xiaoyan holds 114,800 shares in the company and intends to sell no more than 11,200 shares [1] - The planned reduction represents a maximum of 0.0044% of the company's total share capital after excluding shares in the repurchase special account [1]